Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_ex31-1.htm |
| EX-21 - EXHIBIT 21 - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_ex21.htm |
| 10-K - FORM 10-K - BRAINSTORM CELL THERAPEUTICS INC. | tm205304d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference to Registration Statement Nos. 333-131880, 333-168763, 333-175460, 333-182546, 333-198391, 333-213714 and 333-228981 on Form S-8 and Nos. 333-201704, 333-201705, 333-204718, 333-225517, 333-225995 and 333-233349 on Form S-3 of our report dated February 18, 2020, relating to the financial statements of BRAINSTORM CELL THERAPEUTICS INC. (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company’s ability to continue as a going concern) appearing in this Annual Report on Form 10-K of BRAINSTORM CELL THERAPEUTICS INC. for the year ended December 31, 2019.
/s/ Brightman Almagor Zohar & Co.
Brightman Almagor Zohar & Co.
a Firm in the Deloitte Global Network
Tel Aviv, Israel
February 18, 2020
1